Shield Therapeutics plc (STX) - Total Assets
Based on the latest financial reports, Shield Therapeutics plc (STX) holds total assets worth GBX62.10 Million GBX (≈ $7.56K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shield Therapeutics plc - Total Assets Trend (2013–2024)
This chart illustrates how Shield Therapeutics plc's total assets have evolved over time, based on quarterly financial data. Also see STX market cap for the company's overall valuation and market capitalisation.
Shield Therapeutics plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Shield Therapeutics plc's total assets of GBX62.10 Million consist of 66.0% current assets and 34.0% non-current assets. Review debt load of Shield Therapeutics plc to assess the company's total debt and financial obligations.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 12.2% |
| Accounts Receivable | GBX20.16 Million | 43.9% |
| Inventory | GBX4.52 Million | 9.9% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX14.51 Million | 31.6% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Shield Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Shield Therapeutics plc (STX) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shield Therapeutics plc's current assets represent 66.0% of total assets in 2024, a decrease from 80.8% in 2013.
- Cash Position: Cash and equivalents constituted 12.2% of total assets in 2024, down from 75.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 18.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 43.9% of total assets.
Shield Therapeutics plc Competitors by Total Assets
Key competitors of Shield Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs443.12 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664
|
China | CN¥14.08 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
Shield Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.83 | 1.05 | 3.46 |
| Quick Ratio | 0.69 | 0.90 | 2.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-8.64 Million | GBX1.02 Million | GBX6.82 Million |
Shield Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Shield Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 76.33 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -5.9% |
| Total Assets | GBX45.90 Million |
| Market Capitalization | $617.24K USD |
Valuation Analysis
Below Book Valuation: The market values Shield Therapeutics plc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shield Therapeutics plc's assets decreased by 5.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shield Therapeutics plc (2013–2024)
The table below shows the annual total assets of Shield Therapeutics plc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX45.90 Million ≈ $5.58K |
-5.95% |
| 2023-12-31 | GBX48.80 Million ≈ $5.94K |
+121.07% |
| 2022-12-31 | GBX22.07 Million ≈ $2.69K |
-50.30% |
| 2021-12-31 | GBX44.41 Million ≈ $5.40K |
+36.54% |
| 2020-12-31 | GBX32.53 Million ≈ $3.96K |
-10.44% |
| 2019-12-31 | GBX36.32 Million ≈ $4.42K |
-16.28% |
| 2018-12-31 | GBX43.38 Million ≈ $5.28K |
-3.53% |
| 2017-12-31 | GBX44.97 Million ≈ $5.47K |
-14.15% |
| 2016-12-31 | GBX52.38 Million ≈ $6.37K |
+1731.61% |
| 2015-12-31 | GBX2.86 Million ≈ $347.98 |
+184.86% |
| 2014-12-31 | GBX1.00 Million ≈ $122.16 |
-50.86% |
| 2013-12-31 | GBX2.04 Million ≈ $248.57 |
-- |
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the… Read more